$RIGL Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in RIGEL PHARMACEUTICALS INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in RIGEL PHARMACEUTICALS INC. Get notifications about new insider transactions in RIGEL PHARMACEUTICALS INC for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Apr 02 2021 | RIGL | RIGEL PHARMACEUTIC ... | VANCE DOLLY | EVP Corp. Affairs, ... | Option Exercise | A | 2.42 | 37,500 | 90,750 | 37,500 | |
Apr 02 2021 | RIGL | RIGEL PHARMACEUTIC ... | Schorno Dean L | EVP &Chief Financia ... | Option Exercise | A | 2.42 | 50,000 | 121,000 | 50,000 | |
Apr 02 2021 | RIGL | RIGEL PHARMACEUTIC ... | RODRIGUEZ RAUL R | CEO, President | Option Exercise | A | 2.42 | 162,500 | 393,250 | 162,500 | |
Jan 29 2021 | RIGL | RIGEL PHARMACEUTIC ... | Dummer Wolfgang | EVP & CMO | Option Exercise | A | 2.38 | 37,500 | 89,250 | 37,500 | |
Jan 29 2021 | RIGL | RIGEL PHARMACEUTIC ... | Dummer Wolfgang | EVP & CMO | Option Exercise | A | 3.54 | 125,000 | 442,500 | 125,000 | |
Jan 29 2021 | RIGL | RIGEL PHARMACEUTIC ... | Santos David A | EVP, Chief Commerci ... | Option Exercise | A | 3.54 | 137,500 | 486,750 | 137,500 | |
Jan 29 2021 | RIGL | RIGEL PHARMACEUTIC ... | Schorno Dean L | EVP &Chief Financia ... | Option Exercise | A | 3.54 | 112,500 | 398,250 | 112,500 | |
Jan 29 2021 | RIGL | RIGEL PHARMACEUTIC ... | VANCE DOLLY | EVP Corp. Affairs, ... | Option Exercise | A | 3.54 | 125,000 | 442,500 | 125,000 | |
Jan 29 2021 | RIGL | RIGEL PHARMACEUTIC ... | RODRIGUEZ RAUL R | CEO, President | Option Exercise | A | 3.54 | 525,000 | 1,858,500 | 525,000 | |
Aug 20 2020 | RIGL | RIGEL PHARMACEUTIC ... | Santos David A | EVP, Chief Commerci ... | Option Exercise | A | 2.52 | 250,000 | 630,000 | 250,000 | |
May 15 2020 | RIGL | RIGEL PHARMACEUTIC ... | Cabatuan Nelson | VP,Finance & Princ. ... | Option Exercise | A | 1.75 | 20,000 | 35,000 | 20,000 | |
May 15 2020 | RIGL | RIGEL PHARMACEUTIC ... | Wasman Jane | Director | Option Exercise | A | 1.77 | 55,000 | 97,075 | 55,000 | |
May 15 2020 | RIGL | RIGEL PHARMACEUTIC ... | Katkin Keith | Director | Option Exercise | A | 1.77 | 55,000 | 97,075 | 55,000 | |
May 15 2020 | RIGL | RIGEL PHARMACEUTIC ... | Cabatuan Nelson | VP,Finance & Princ. ... | Option Exercise | A | 1.75 | 20,000 | 35,000 | 20,000 | |
May 15 2020 | RIGL | RIGEL PHARMACEUTIC ... | Kotzin Brian L. | Director | Option Exercise | A | 1.77 | 55,000 | 97,075 | 55,000 | |
May 15 2020 | RIGL | RIGEL PHARMACEUTIC ... | LAPOINTE ANTHONY GREGG | Director | Option Exercise | A | 1.77 | 55,000 | 97,075 | 55,000 | |
May 15 2020 | RIGL | RIGEL PHARMACEUTIC ... | Wasman Jane | Director | Option Exercise | A | 1.77 | 55,000 | 97,075 | 55,000 | |
May 15 2020 | RIGL | RIGEL PHARMACEUTIC ... | Goodwin Bradford S | Director | Option Exercise | A | 1.77 | 55,000 | 97,075 | 55,000 | |
May 15 2020 | RIGL | RIGEL PHARMACEUTIC ... | Katkin Keith | Director | Option Exercise | A | 1.77 | 55,000 | 97,075 | 55,000 | |
May 15 2020 | RIGL | RIGEL PHARMACEUTIC ... | Kotzin Brian L. | Director | Option Exercise | A | 1.77 | 55,000 | 97,075 | 55,000 | |
May 15 2020 | RIGL | RIGEL PHARMACEUTIC ... | LAPOINTE ANTHONY GREGG | Director | Option Exercise | A | 1.77 | 55,000 | 97,075 | 55,000 | |
May 15 2020 | RIGL | RIGEL PHARMACEUTIC ... | Goodwin Bradford S | Director | Option Exercise | A | 1.77 | 55,000 | 97,075 | 55,000 | |
May 15 2020 | RIGL | RIGEL PHARMACEUTIC ... | MOOS WALTER H | Director | Option Exercise | A | 1.77 | 55,000 | 97,075 | 55,000 | |
May 15 2020 | RIGL | RIGEL PHARMACEUTIC ... | LYONS GARY A | Director | Option Exercise | A | 1.77 | 55,000 | 97,075 | 55,000 | |
May 15 2020 | RIGL | RIGEL PHARMACEUTIC ... | MOOS WALTER H | Director | Option Exercise | A | 1.77 | 55,000 | 97,075 | 55,000 | |
May 15 2020 | RIGL | RIGEL PHARMACEUTIC ... | LYONS GARY A | Director | Option Exercise | A | 1.77 | 55,000 | 97,075 | 55,000 | |
Feb 07 2020 | RIGL | RIGEL PHARMACEUTIC ... | Cabatuan Nelson | VP,Finance & Princ. ... | Option Exercise | A | 2.42 | 90,000 | 217,800 | 90,000 | |
Feb 07 2020 | RIGL | RIGEL PHARMACEUTIC ... | VANCE DOLLY | EVP Corp. Affairs, ... | Option Exercise | A | 2.42 | 150,000 | 363,000 | 150,000 | |
Feb 07 2020 | RIGL | RIGEL PHARMACEUTIC ... | Schorno Dean L | EVP &Chief Financia ... | Option Exercise | A | 2.42 | 200,000 | 484,000 | 200,000 | |
Feb 07 2020 | RIGL | RIGEL PHARMACEUTIC ... | RODRIGUEZ RAUL R | CEO, President | Option Exercise | A | 2.42 | 650,000 | 1,573,000 | 650,000 | |
Nov 20 2019 | RIGL | RIGEL PHARMACEUTIC ... | Schorno Dean L | EVP &Chief Financia ... | Option Exercise | A | 3.44 | 83,750 | 288,100 | 83,750 | |
Nov 20 2019 | RIGL | RIGEL PHARMACEUTIC ... | Lasaga Joseph | Sr.VP Bus.Dev.Allia ... | Option Exercise | A | 4.49 | 43,750 | 196,438 | 43,750 | |
Nov 20 2019 | RIGL | RIGEL PHARMACEUTIC ... | Masuda Esteban | Sr. VP Research | Option Exercise | S | 4.49 | 62,500 | 280,625 | 62,500 | |
Nov 20 2019 | RIGL | RIGEL PHARMACEUTIC ... | Mayer Eldon C. III | EVP & Chief Commerc ... | Option Exercise | A | 4.49 | 75,000 | 336,750 | 75,000 | |
Nov 20 2019 | RIGL | RIGEL PHARMACEUTIC ... | VANCE DOLLY | EVP Corp. Affairs, ... | Option Exercise | A | 4.49 | 75,000 | 336,750 | 75,000 | |
Nov 20 2019 | RIGL | RIGEL PHARMACEUTIC ... | RODRIGUEZ RAUL R | CEO, President | Option Exercise | A | 4.49 | 237,500 | 1,066,375 | 237,500 | |
Nov 20 2019 | RIGL | RIGEL PHARMACEUTIC ... | Dummer Wolfgang | EVP & CMO | Option Exercise | A | 2.25 | 220,000 | 495,000 | 220,000 | |
May 24 2019 | RIGL | RIGEL PHARMACEUTIC ... | Katkin Keith | Director | Option Exercise | A | 2.02 | 55,000 | 111,100 | 55,000 | |
May 24 2019 | RIGL | RIGEL PHARMACEUTIC ... | Goodwin Bradford S | Director | Option Exercise | A | 2.02 | 55,000 | 111,100 | 55,000 | |
May 24 2019 | RIGL | RIGEL PHARMACEUTIC ... | Kotzin Brian L. | Director | Option Exercise | A | 2.02 | 55,000 | 111,100 | 55,000 | |
May 24 2019 | RIGL | RIGEL PHARMACEUTIC ... | Wasman Jane | Director | Option Exercise | A | 2.02 | 13,750 | 27,775 | 13,750 | |
May 24 2019 | RIGL | RIGEL PHARMACEUTIC ... | LAPOINTE ANTHONY GREGG | Director | Option Exercise | A | 2.02 | 55,000 | 111,100 | 55,000 | |
May 24 2019 | RIGL | RIGEL PHARMACEUTIC ... | LYONS GARY A | Director | Option Exercise | A | 2.02 | 55,000 | 111,100 | 55,000 | |
May 24 2019 | RIGL | RIGEL PHARMACEUTIC ... | MOOS WALTER H | Director | Option Exercise | A | 2.02 | 55,000 | 111,100 | 55,000 | |
May 23 2019 | RIGL | RIGEL PHARMACEUTIC ... | Schorno Dean L | EVP &Chief Financia ... | Buy | P | 2.13 | 3,274 | 6,971 | 50,000 | 46.7 K to 50 K (+7.01 %) |
May 23 2019 | RIGL | RIGEL PHARMACEUTIC ... | Schorno Dean L | EVP &Chief Financia ... | Buy | P | 2.13 | 46,726 | 99,573 | 46,726 | 0 to 46.7 K |
Apr 03 2019 | RIGL | RIGEL PHARMACEUTIC ... | Wasman Jane | Director | Option Exercise | A | 2.42 | 80,000 | 193,600 | 80,000 | |
Mar 22 2019 | RIGL | RIGEL PHARMACEUTIC ... | Schorno Dean L | EVP &Chief Financia ... | Option Exercise | A | 3.44 | 83,750 | 288,100 | 83,750 | |
Mar 22 2019 | RIGL | RIGEL PHARMACEUTIC ... | Markel Stacy | EVP Human Resources | Option Exercise | A | 3.94 | 62,500 | 246,250 | 62,500 | |
Mar 22 2019 | RIGL | RIGEL PHARMACEUTIC ... | Lasaga Joseph | Sr.VP Bus.Dev.Allia ... | Option Exercise | A | 4.49 | 43,750 | 196,438 | 43,750 | |
Mar 22 2019 | RIGL | RIGEL PHARMACEUTIC ... | Masuda Esteban | Sr. VP Research | Option Exercise | A | 4.49 | 62,500 | 280,625 | 62,500 | |
Mar 22 2019 | RIGL | RIGEL PHARMACEUTIC ... | Mayer Eldon C. III | EVP & Chief Commerc ... | Option Exercise | A | 4.49 | 75,000 | 336,750 | 75,000 | |
Mar 22 2019 | RIGL | RIGEL PHARMACEUTIC ... | VANCE DOLLY | EVP Corp. Affairs, ... | Option Exercise | A | 4.49 | 75,000 | 336,750 | 75,000 | |
Mar 22 2019 | RIGL | RIGEL PHARMACEUTIC ... | Duliege Anne-Marie | EVP & Chief Medical ... | Option Exercise | A | 4.49 | 75,000 | 336,750 | 75,000 | |
Mar 22 2019 | RIGL | RIGEL PHARMACEUTIC ... | RODRIGUEZ RAUL R | CEO, President | Option Exercise | A | 4.49 | 237,500 | 1,066,375 | 237,500 | |
Jan 25 2019 | RIGL | RIGEL PHARMACEUTIC ... | Cabatuan Nelson | Principal Accountin ... | Option Exercise | A | 2.00 | 60,000 | 120,000 | 60,000 | |
Jan 25 2019 | RIGL | RIGEL PHARMACEUTIC ... | Lasaga Joseph | Sr.VP Bus.Dev.Allia ... | Option Exercise | A | 2.00 | 100,000 | 200,000 | 100,000 | |
Jan 25 2019 | RIGL | RIGEL PHARMACEUTIC ... | Masuda Esteban | Sr. VP Research | Option Exercise | A | 2.00 | 100,000 | 200,000 | 100,000 | |
Jan 25 2019 | RIGL | RIGEL PHARMACEUTIC ... | Markel Stacy | EVP Human Resources | Option Exercise | A | 2.00 | 137,500 | 275,000 | 137,500 | |
Jan 25 2019 | RIGL | RIGEL PHARMACEUTIC ... | Mayer Eldon C. III | EVP & Chief Commerc ... | Option Exercise | A | 2.00 | 200,000 | 400,000 | 200,000 | |
Jan 25 2019 | RIGL | RIGEL PHARMACEUTIC ... | Schorno Dean L | EVP &Chief Financia ... | Option Exercise | A | 2.00 | 162,500 | 325,000 | 162,500 | |
Jan 25 2019 | RIGL | RIGEL PHARMACEUTIC ... | Duliege Anne-Marie | EVP & Chief Medical ... | Option Exercise | A | 2.00 | 162,500 | 325,000 | 162,500 | |
Jan 25 2019 | RIGL | RIGEL PHARMACEUTIC ... | VANCE DOLLY | EVP Corp. Affairs, ... | Option Exercise | A | 2.00 | 162,500 | 325,000 | 162,500 | |
Jan 25 2019 | RIGL | RIGEL PHARMACEUTIC ... | RODRIGUEZ RAUL R | CEO, President | Option Exercise | A | 2.00 | 600,000 | 1,200,000 | 600,000 | |
Oct 16 2018 | RIGL | RIGEL PHARMACEUTIC ... | Cabatuan Nelson | Principal Accountin ... | Sell | S | 3.12 | 10,000 | 31,200 | 58 | 10.1 K to 58 (-99.42 %) |
Sep 19 2018 | RIGL | RIGEL PHARMACEUTIC ... | Duliege Anne-Marie | EVP & Chief Medical ... | Option Exercise | M | 2.11 | 37,500 | 79,125 | 112,500 | |
Sep 19 2018 | RIGL | RIGEL PHARMACEUTIC ... | Duliege Anne-Marie | EVP & Chief Medical ... | Option Exercise | M | 2.54 | 115,500 | 293,370 | 268,000 | |
Sep 19 2018 | RIGL | RIGEL PHARMACEUTIC ... | Duliege Anne-Marie | EVP & Chief Medical ... | Sell | S | 3.50 | 37,500 | 131,250 | 0 | 37.5 K to 0 (-100.00 %) |
Sep 19 2018 | RIGL | RIGEL PHARMACEUTIC ... | Duliege Anne-Marie | EVP & Chief Medical ... | Buy | M | 2.11 | 37,500 | 79,125 | 37,500 | 0 to 37.5 K |
Sep 19 2018 | RIGL | RIGEL PHARMACEUTIC ... | Duliege Anne-Marie | EVP & Chief Medical ... | Sell | S | 3.50 | 115,500 | 404,250 | 0 | 115.5 K to 0 (-100.00 %) |
Sep 19 2018 | RIGL | RIGEL PHARMACEUTIC ... | Duliege Anne-Marie | EVP & Chief Medical ... | Buy | M | 2.54 | 115,500 | 293,370 | 115,500 | 0 to 115.5 K |
Sep 12 2018 | RIGL | RIGEL PHARMACEUTIC ... | Mayer Eldon C. III | EVP & Chief Commerc ... | Buy | P | 3.23 | 50,000 | 161,340 | 215,000 | 165 K to 215 K (+30.30 %) |
Sep 12 2018 | RIGL | RIGEL PHARMACEUTIC ... | Mayer Eldon C. III | EVP & Chief Commerc ... | Buy | P | 3.28 | 50,000 | 164,210 | 165,000 | 115 K to 165 K (+43.48 %) |
Sep 06 2018 | RIGL | RIGEL PHARMACEUTIC ... | Duliege Anne-Marie | EVP & Chief Medical ... | Option Exercise | M | 2.54 | 16,500 | 41,910 | 383,500 | |
Sep 06 2018 | RIGL | RIGEL PHARMACEUTIC ... | Duliege Anne-Marie | EVP & Chief Medical ... | Sell | S | 3.51 | 16,500 | 57,861 | 0 | 16.5 K to 0 (-100.00 %) |
Sep 06 2018 | RIGL | RIGEL PHARMACEUTIC ... | Duliege Anne-Marie | EVP & Chief Medical ... | Buy | M | 2.54 | 16,500 | 41,910 | 16,500 | 0 to 16.5 K |
Aug 27 2018 | RIGL | RIGEL PHARMACEUTIC ... | Mayer Eldon C. III | EVP & Chief Commerc ... | Buy | P | 2.82 | 100,000 | 282,320 | 115,000 | 15 K to 115 K (+666.67 %) |
Aug 21 2018 | RIGL | RIGEL PHARMACEUTIC ... | RODRIGUEZ RAUL R | CEO, President | Buy | P | 2.63 | 114,000 | 300,002 | 173,519 | 59.5 K to 173.5 K (+191.54 %) |
Aug 16 2018 | RIGL | RIGEL PHARMACEUTIC ... | Cabatuan Nelson | Principal Accountin ... | Option Exercise | A | 2.76 | 20,000 | 55,200 | 20,000 | |
Jul 05 2018 | RIGL | RIGEL PHARMACEUTIC ... | Duliege Anne-Marie | EVP & Chief Medical ... | Sell | S | 2.79 | 5,000 | 13,932 | 0 | 5 K to 0 (-100.00 %) |
Jun 06 2018 | RIGL | RIGEL PHARMACEUTIC ... | Schorno Dean L | EVP &Chief Financia ... | Option Exercise | A | 3.44 | 167,500 | 576,200 | 167,500 | |
May 18 2018 | RIGL | RIGEL PHARMACEUTIC ... | RINGROSE PETER S | Director | Option Exercise | A | 3.98 | 40,000 | 159,200 | 40,000 | |
May 18 2018 | RIGL | RIGEL PHARMACEUTIC ... | Kotzin Brian L. | Director | Option Exercise | A | 3.98 | 40,000 | 159,200 | 40,000 | |
May 18 2018 | RIGL | RIGEL PHARMACEUTIC ... | MOOS WALTER H | Director | Option Exercise | A | 3.98 | 40,000 | 159,200 | 40,000 | |
May 18 2018 | RIGL | RIGEL PHARMACEUTIC ... | LYONS GARY A | Director | Option Exercise | A | 3.98 | 40,000 | 159,200 | 40,000 | |
May 18 2018 | RIGL | RIGEL PHARMACEUTIC ... | LAPOINTE ANTHONY GREGG | Director | Option Exercise | A | 3.98 | 30,000 | 119,400 | 30,000 | |
May 18 2018 | RIGL | RIGEL PHARMACEUTIC ... | Katkin Keith | Director | Option Exercise | A | 3.98 | 40,000 | 159,200 | 40,000 | |
May 18 2018 | RIGL | RIGEL PHARMACEUTIC ... | Goodwin Bradford S | Director | Option Exercise | A | 3.98 | 40,000 | 159,200 | 40,000 | |
May 11 2018 | RIGL | RIGEL PHARMACEUTIC ... | Masuda Esteban | Sr. VP Research | Option Exercise | A | 2.11 | 50,000 | 105,500 | 50,000 | |
May 11 2018 | RIGL | RIGEL PHARMACEUTIC ... | Mayer Eldon C. III | EVP & Chief Commerc ... | Option Exercise | A | 2.11 | 50,000 | 105,500 | 50,000 | |
May 11 2018 | RIGL | RIGEL PHARMACEUTIC ... | VANCE DOLLY | EVP Corp. Affairs, ... | Option Exercise | A | 2.11 | 150,000 | 316,500 | 150,000 | |
May 11 2018 | RIGL | RIGEL PHARMACEUTIC ... | Duliege Anne-Marie | EVP & Chief Medical ... | Option Exercise | A | 2.11 | 150,000 | 316,500 | 150,000 | |
May 11 2018 | RIGL | RIGEL PHARMACEUTIC ... | RODRIGUEZ RAUL R | CEO, President | Option Exercise | A | 2.11 | 450,000 | 949,500 | 450,000 | |
May 11 2018 | RIGL | RIGEL PHARMACEUTIC ... | Lasaga Joseph | VP Bus. Dev.& Allia ... | Option Exercise | A | 2.11 | 25,000 | 52,750 | 25,000 | |
Apr 24 2018 | RIGL | RIGEL PHARMACEUTIC ... | Duliege Anne-Marie | EVP & Chief Medical ... | Sell | S | 4.11 | 5,000 | 20,550 | 0 | 5 K to 0 (-100.00 %) |
Mar 23 2018 | RIGL | RIGEL PHARMACEUTIC ... | Markel Stacy | EVP Human Resources | Option Exercise | A | 3.94 | 125,000 | 492,500 | 125,000 | |
Jan 26 2018 | RIGL | RIGEL PHARMACEUTIC ... | Cabatuan Nelson | Principal Accountin ... | Option Exercise | A | 4.49 | 24,000 | 107,760 | 24,000 | |
Jan 26 2018 | RIGL | RIGEL PHARMACEUTIC ... | Lasaga Joseph | VP Bus. Dev.& Allia ... | Option Exercise | A | 4.49 | 87,500 | 392,875 | 87,500 | |
Jan 26 2018 | RIGL | RIGEL PHARMACEUTIC ... | Masuda Esteban | Sr. VP Research | Option Exercise | A | 4.49 | 125,000 | 561,250 | 125,000 | |
Jan 26 2018 | RIGL | RIGEL PHARMACEUTIC ... | Mayer Eldon C. III | EVP & Chief Commerc ... | Option Exercise | A | 4.49 | 150,000 | 673,500 | 150,000 | |
Jan 26 2018 | RIGL | RIGEL PHARMACEUTIC ... | Duliege Anne-Marie | Chief Medical Offic ... | Option Exercise | A | 4.49 | 150,000 | 673,500 | 150,000 | |
Jan 26 2018 | RIGL | RIGEL PHARMACEUTIC ... | VANCE DOLLY | EVP Corp. Affairs, ... | Option Exercise | A | 4.49 | 150,000 | 673,500 | 150,000 | |
Jan 26 2018 | RIGL | RIGEL PHARMACEUTIC ... | RODRIGUEZ RAUL R | CEO, President | Option Exercise | A | 4.49 | 475,000 | 2,132,750 | 475,000 | |
Nov 07 2017 | RIGL | RIGEL PHARMACEUTIC ... | Maynard Ryan D | EVP & CFO | Option Exercise | M | 2.14 | 100,000 | 214,000 | 75,000 | |
Nov 07 2017 | RIGL | RIGEL PHARMACEUTIC ... | Maynard Ryan D | EVP & CFO | Sell | S | 3.90 | 100,000 | 390,000 | 0 | 100 K to 0 (-100.00 %) |
Nov 07 2017 | RIGL | RIGEL PHARMACEUTIC ... | Maynard Ryan D | EVP & CFO | Buy | M | 2.14 | 100,000 | 214,000 | 100,000 | 0 to 100 K |
Nov 02 2017 | RIGL | RIGEL PHARMACEUTIC ... | LAPOINTE ANTHONY GREGG | Director | Option Exercise | A | 3.80 | 80,000 | 304,000 | 80,000 | |
Aug 23 2017 | RIGL | RIGEL PHARMACEUTIC ... | Kotzin Brian L. | Director | Option Exercise | A | 2.20 | 80,000 | 176,000 | 80,000 | |
Jul 07 2017 | RIGL | RIGEL PHARMACEUTIC ... | Duliege Anne-Marie | Chief Medical Offic ... | Sell | S | 2.69 | 5,000 | 13,427 | 0 | 5 K to 0 (-100.00 %) |
May 12 2017 | RIGL | RIGEL PHARMACEUTIC ... | RINGROSE PETER S | Director | Option Exercise | A | 2.61 | 40,000 | 104,400 | 40,000 | |
May 12 2017 | RIGL | RIGEL PHARMACEUTIC ... | MOOS WALTER H | Director | Option Exercise | A | 2.61 | 40,000 | 104,400 | 40,000 | |
May 12 2017 | RIGL | RIGEL PHARMACEUTIC ... | Katkin Keith | Director | Option Exercise | A | 2.61 | 40,000 | 104,400 | 40,000 | |
May 12 2017 | RIGL | RIGEL PHARMACEUTIC ... | Goodwin Bradford S | Director | Option Exercise | A | 2.61 | 40,000 | 104,400 | 40,000 | |
May 12 2017 | RIGL | RIGEL PHARMACEUTIC ... | LYONS GARY A | Director | Option Exercise | A | 2.61 | 40,000 | 104,400 | 40,000 | |
Apr 21 2017 | RIGL | RIGEL PHARMACEUTIC ... | VANCE DOLLY | EVP Corp. Affairs, ... | Option Exercise | A | 2.74 | 150,000 | 411,000 | 150,000 | |
Apr 21 2017 | RIGL | RIGEL PHARMACEUTIC ... | VANCE DOLLY | EVP Corp. Affairs, ... | Option Exercise | A | 3.59 | 62,500 | 224,375 | 62,500 | |
Apr 21 2017 | RIGL | RIGEL PHARMACEUTIC ... | Maynard Ryan D | EVP & CFO | Option Exercise | A | 2.74 | 150,000 | 411,000 | 150,000 | |
Apr 21 2017 | RIGL | RIGEL PHARMACEUTIC ... | Maynard Ryan D | EVP & CFO | Option Exercise | A | 3.59 | 62,500 | 224,375 | 62,500 | |
Apr 21 2017 | RIGL | RIGEL PHARMACEUTIC ... | RODRIGUEZ RAUL R | CEO, President | Option Exercise | A | 2.74 | 400,000 | 1,096,000 | 400,000 | |
Apr 21 2017 | RIGL | RIGEL PHARMACEUTIC ... | RODRIGUEZ RAUL R | CEO, President | Option Exercise | A | 3.59 | 75,000 | 269,250 | 75,000 | |
Feb 06 2017 | RIGL | RIGEL PHARMACEUTIC ... | Lasaga Joseph | VP Bus. Dev.& Allia ... | Option Exercise | A | 2.11 | 25,000 | 52,750 | 25,000 | |
Feb 06 2017 | RIGL | RIGEL PHARMACEUTIC ... | Masuda Esteban | Sr. VP Research | Option Exercise | A | 2.11 | 50,000 | 105,500 | 50,000 | |
Feb 06 2017 | RIGL | RIGEL PHARMACEUTIC ... | Mayer Eldon C. III | EVP & Chief Commerc ... | Option Exercise | A | 2.11 | 50,000 | 105,500 | 50,000 | |
Feb 06 2017 | RIGL | RIGEL PHARMACEUTIC ... | Duliege Anne-Marie | Chief Medical Offic ... | Option Exercise | A | 2.11 | 150,000 | 316,500 | 150,000 | |
Feb 06 2017 | RIGL | RIGEL PHARMACEUTIC ... | Maynard Ryan D | EVP & CFO | Option Exercise | A | 2.11 | 150,000 | 316,500 | 150,000 | |
Feb 06 2017 | RIGL | RIGEL PHARMACEUTIC ... | VANCE DOLLY | EVP Corp. Affairs, ... | Option Exercise | A | 2.11 | 150,000 | 316,500 | 150,000 | |
Feb 06 2017 | RIGL | RIGEL PHARMACEUTIC ... | RODRIGUEZ RAUL R | CEO, President | Option Exercise | A | 2.11 | 450,000 | 949,500 | 450,000 | |
Jan 13 2017 | RIGL | RIGEL PHARMACEUTIC ... | Duliege Anne-Marie | Chief Medical Offic ... | Sell | S | 2.41 | 5,000 | 12,028 | 0 | 5 K to 0 (-100.00 %) |
Oct 11 2016 | RIGL | RIGEL PHARMACEUTIC ... | Lasaga Joseph | VP Bus. Dev.& Allia ... | Option Exercise | A | 3.92 | 150,000 | 588,000 | 150,000 | |
Oct 11 2016 | RIGL | RIGEL PHARMACEUTIC ... | Mayer Eldon C. III | EVP &Chief Commerci ... | Option Exercise | A | 3.92 | 300,000 | 1,176,000 | 300,000 | |
Sep 01 2016 | RIGL | RIGEL PHARMACEUTIC ... | PAYAN DONALD G | EVP, Pres. Discover ... | Sell | S | 4.00 | 5,303 | 21,214 | 53,031 | 58.3 K to 53 K (-9.09 %) |
May 12 2016 | RIGL | RIGEL PHARMACEUTIC ... | SHERWIN STEPHEN A | Director | Option Exercise | A | 2.40 | 40,000 | 96,000 | 40,000 | |
May 12 2016 | RIGL | RIGEL PHARMACEUTIC ... | RINGROSE PETER S | Director | Option Exercise | A | 2.40 | 40,000 | 96,000 | 40,000 | |
May 12 2016 | RIGL | RIGEL PHARMACEUTIC ... | LYONS GARY A | Director | Option Exercise | A | 2.40 | 40,000 | 96,000 | 40,000 | |
May 12 2016 | RIGL | RIGEL PHARMACEUTIC ... | MOOS WALTER H | Director | Option Exercise | A | 2.40 | 40,000 | 96,000 | 40,000 | |
May 12 2016 | RIGL | RIGEL PHARMACEUTIC ... | Katkin Keith | Director | Option Exercise | A | 2.40 | 40,000 | 96,000 | 40,000 | |
May 12 2016 | RIGL | RIGEL PHARMACEUTIC ... | Goodwin Bradford S | Director | Option Exercise | A | 2.40 | 40,000 | 96,000 | 40,000 | |
May 09 2016 | RIGL | RIGEL PHARMACEUTIC ... | Duliege Anne-Marie | Chief Medical Offic ... | Option Exercise | A | 2.54 | 400,000 | 1,016,000 | 400,000 | |
Apr 06 2016 | RIGL | RIGEL PHARMACEUTIC ... | VANCE DOLLY | EVP Corp. Affairs, ... | Option Exercise | A | 2.14 | 175,000 | 374,500 | 175,000 | |
Apr 06 2016 | RIGL | RIGEL PHARMACEUTIC ... | VANCE DOLLY | EVP Corp. Affairs, ... | Option Exercise | A | 3.59 | 62,500 | 224,375 | 62,500 | |
Apr 06 2016 | RIGL | RIGEL PHARMACEUTIC ... | Maynard Ryan D | EVP & CFO | Option Exercise | A | 2.14 | 175,000 | 374,500 | 175,000 | |
Apr 06 2016 | RIGL | RIGEL PHARMACEUTIC ... | Maynard Ryan D | EVP & CFO | Option Exercise | A | 3.59 | 62,500 | 224,375 | 62,500 | |
Apr 06 2016 | RIGL | RIGEL PHARMACEUTIC ... | PAYAN DONALD G | EVP, Pres. Discover ... | Option Exercise | A | 2.14 | 200,000 | 428,000 | 200,000 | |
Apr 06 2016 | RIGL | RIGEL PHARMACEUTIC ... | PAYAN DONALD G | EVP, Pres. Discover ... | Option Exercise | A | 3.59 | 75,000 | 269,250 | 75,000 | |
Apr 06 2016 | RIGL | RIGEL PHARMACEUTIC ... | RODRIGUEZ RAUL R | CEO, President | Option Exercise | A | 2.14 | 450,000 | 963,000 | 450,000 | |
Apr 06 2016 | RIGL | RIGEL PHARMACEUTIC ... | RODRIGUEZ RAUL R | CEO, President | Option Exercise | A | 3.59 | 75,000 | 269,250 | 75,000 | |
Jan 28 2016 | RIGL | RIGEL PHARMACEUTIC ... | Maynard Ryan D | EVP & CFO | Option Exercise | A | 2.74 | 150,000 | 411,000 | 150,000 | |
Jan 28 2016 | RIGL | RIGEL PHARMACEUTIC ... | VANCE DOLLY | EVP Corp. Affairs, ... | Option Exercise | A | 2.74 | 150,000 | 411,000 | 150,000 | |
Jan 28 2016 | RIGL | RIGEL PHARMACEUTIC ... | Grossbard Elliott B | EVP, CMO | Option Exercise | A | 2.74 | 150,000 | 411,000 | 150,000 | |
Jan 28 2016 | RIGL | RIGEL PHARMACEUTIC ... | PAYAN DONALD G | EVP, Pres. Discover ... | Option Exercise | A | 2.74 | 165,000 | 452,100 | 165,000 |